Minaris Advanced Therapies — formed through the merger of Minaris Regenerative Medicine and WuXi Advanced Therapies, following acquisition by Altaris Capital Partners — is a global CDMO specializing in cell therapy products. With over 45 years of combined experience, the company provides end-to-end clinical and commercial manufacturing, development solutions, and advanced technologies. Its six state-of-the-art facilities across the United States, Europe, and Asia enable the production and supply of life-changing therapies to patients worldwide with high quality and reliability.